DASL-HiCaP

Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation and definitive or salvage radiation in very

Acronym:

DASL-HiCaP

ACTRN/NCT /ethics:

NCT04136353

Scientific title:

Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (DASL-HiCaP)

Sponsor / Cooperative group:

University of Sydney